8-K: Helix SPAC Retains $120M, Secures $261M PIPE for BBOT

Helix Acquisition Corp. II successfully retained over 60% of its trust account funds and secured a significant PIPE financing, paving the way for its business combination with BridgeBio Oncology Therapeutics.

Summary

• Helix Acquisition Corp. II (Helix) and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, BBOT) jointly announced that Helix retained approximately $120 million in its trust account, representing more than 60% of the cash held in trust after public shareholder redemptions.
• The deadline for submitting redemption requests was July 31, 2025.
• The transaction is expected to raise an aggregate of approximately $382 million in gross proceeds.
• This total includes the $120 million from Helix's trust account and approximately $261 million from a common stock private placement (PIPE) transaction.
• The PIPE financing was led by Cormorant Asset Management and included other notable investors such as ADAR1 Capital Management, BC Capital, Deerfield Management Company, Enavate Sciences, Eventide Asset Management, Novo Holdings A/S, Octagon Capital, Omega Funds, Paradigm BioCapital Advisors, StemPoint Capital LP, Surveyor Capital (a Citadel company), and Wellington Management.
• Helix and BBOT intend to proceed expeditiously with the closing of the business combination, subject to the satisfaction or waiver of closing conditions.
• BBOT is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for RAS and PI3K malignancies.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the exceptional trust account retention rate (2nd lowest redemption in biotech de-SPACs since 2022) and the successful securing of a substantial PIPE financing, indicating strong investor confidence and a clear path to closing the business combination with significant capital.

Positives

• Helix retained approximately $120 million, or more than 60%, of its trust account funds, indicating strong shareholder support for the business combination.
• The redemption rate achieved is the 2nd lowest for a biotech de-SPAC transaction since 2022, highlighting exceptional investor confidence compared to industry trends.
• A substantial PIPE financing of approximately $261 million was secured from a diverse group of leading institutional investors, significantly bolstering the combined company's capital.
• The combined gross proceeds of approximately $382 million provide substantial capital for BridgeBio Oncology Therapeutics' clinical-stage pipeline and operations.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact the business combination.
• The ability of the parties to successfully consummate the business combination is subject to various factors.
• Satisfaction or waiver of the conditions to the consummation of the Business Combination, including the minimum cash condition, is not guaranteed.
• The combined company's ability to meet Nasdaq's initial listing standards and list its stock on Nasdaq is a condition for the transaction.
• Additional risks are detailed in Helix's definitive proxy statement/prospectus filed with the SEC on July 10, 2025 (File No. 333-288222), as supplemented on July 21, 2025, particularly in the Risk Factors section.
• There may be additional unknown or currently immaterial risks that could cause actual results to differ materially from forward-looking statements.

Future Outlook

Helix and BBOT anticipate proceeding expeditiously with the closing of the business combination, subject to the satisfaction or waiver of closing conditions. The combined company expects to have approximately $382 million in gross proceeds available to support its operations and clinical pipeline.

Management Comments

• Helix and BBOT intend to proceed expeditiously with the closing of the business combination, subject to the satisfaction or waiver of closing conditions.

Industry Context

This announcement reflects a significant development in the SPAC market, particularly within the biotechnology sector. The successful retention of a high percentage of trust account funds and a substantial PIPE financing indicate a strong appetite for de-SPAC transactions involving promising clinical-stage biopharmaceutical companies, despite broader market volatility and past challenges faced by SPACs. BridgeBio Oncology Therapeutics' focus on RAS and PI3K malignancies positions it in a high-potential area of oncology drug development.

Comparison to Industry Standards

• The redemption rate achieved by Helix is noted as the '2nd lowest redemption rate for a biotech de-SPAC transaction since 2022'. This directly benchmarks the transaction's success against recent industry performance, indicating superior investor retention compared to most comparable biotech SPAC mergers.

Related Party Transactions

• Cormorant Asset Management, the sponsor of Helix Acquisition Corp. II, is also leading the PIPE financing, indicating a significant related-party investment in the combined entity.

Stakeholder Impact

• Shareholders of Helix Acquisition Corp. II who did not redeem their shares will become shareholders of the combined company, benefiting from the successful capital raise and the merger with a clinical-stage biopharmaceutical company.
• New investors participating in the PIPE financing will gain equity in the combined entity, supporting its future growth.
• BridgeBio Oncology Therapeutics will receive substantial capital (approximately $382 million gross proceeds) to advance its pipeline of novel small molecule therapeutics, benefiting its employees and potentially patients.
• Cormorant Asset Management strengthens its strategic position through both its sponsorship of Helix and its lead role in the PIPE financing.

Next Steps

• Proceed expeditiously with the closing of the business combination between Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics.
• Satisfy or waive remaining closing conditions for the business combination.

Key Dates

Recommendation

The successful retention of over 60% of the trust account, coupled with a substantial $261 million PIPE financing, demonstrates strong investor confidence and provides significant capital for the combined entity. The stated '2nd lowest redemption rate for a biotech de-SPAC transaction since 2022' is a highly positive indicator, suggesting a well-received transaction in a challenging SPAC environment. This robust financial position and market validation significantly de-risk the de-SPAC process for Helix and provide BridgeBio Oncology Therapeutics with ample resources to advance its clinical programs, making the combined entity an attractive investment.

Keywords

SPAC, biotech, de-SPAC, BridgeBio Oncology Therapeutics, Helix Acquisition Corp. II, HLXB, PIPE financing, trust account, redemption rate, clinical-stage biopharmaceutical, RAS malignancies, PI3K malignancies, Cormorant Asset Management